Coronavirus (COVID-19)

Please continue to wear your face mask while you are in our hospitals and community services.

For health information and advice, read our pages on coronavirus. Learn about the government response to coronavirus on GOV.UK

Pharmacological Therapies Policy

External Requests for Restricted Policies - Click here for information on how to request Restricted Policies via an FOI Request

Pharmacological Therapies Policy (387kB)

PPT-PGN-01 (745kB)

Psychotropic Induced Sexual Dysfunction


The Safe Use of AstraZeneca COVID-19 (ChAdOx1 (recombinant)) Vaccine-Restricted Available at Local Intranet

PPT-PGN-03 (855kB)

Anticoagulation Therapy

PPT-PGN-04 (587kB)

Drug Allergy

PPT-PGN-04 - Appendix 1 (214kB)

Drug Allergy Reaction Types and Timescales

PPT-PGN-05 (460kB)

Safe Prescribing of Clozapine

PPT-PGN-05 - Appendix 1 (196kB)

Monitoring requirements for patients prescribed Clozapine

PPT-PGN-05 - Appendix 2 (66kB)

Clozapine titration/retitration prescription

PPT-PGN-05 - Appendix 3 (145kB)

Clozapine Initiation Monitoring

PPT-PGN-05 - Appendix 4 (70kB)

Clozapine Clinic Referral Form

PPT-PGN-05 - Appendix 5 (197kB)

Contact Details

PPT-PGN-05 - Appendix 6 (63kB)

Shared Care agreement and GP Letter Template

PPT-PGN-05 - Appendix 7 (61kB)

Clozapine Clinic Standard Work

PPT-PGN-05 - Appendix 8 (175kB)

Guide to Interpretation of Clozapine Plasma Levels

PPT-PGN-05 - Appendix 9 (143kB)

RED result protocol

PPT-PGN-05 - Appendix 10 (160kB)

AMBER result protocol

PPT-PGN-05 - Appendix 11 (184kB)

Denzapine Rechallenge process

PPT-PGN-05 - Appendix 12 (438kB)

Treatment Break Protocol

PPT-PGN-05 - Appendix 13 (135kB)

Retitration by the CRHT

PPT-PGN-05 - Appendix 14 (142kB)

Clozapine Related Constipation

PPT-PGN-05 - Appendix 15 (151kB)

Clozapine related hypersalivation

PPT-PGN-05 - Appendix 16 (205kB)

Clozapine and smoking

PPT-PGN-06 (443kB)

Guidelines for the Safe Prescribing and Administration of Insulin

PPT-PGN-06 - Appendix 1 (36kB)

Capillary Blood Glucose (CBG) Monitoring Chart

PPT-PGN-06 - Appendix 2 (29kB)

Variable Dose Insulin Chart

PPT-PGN-06 - Appendix 3 (306kB)

Management of Hypoglycaemia

PPT-PGN-08 (818kB)

Physical Health Monitoring of Patients Prescribed Anti Psychotics and Other Psychotropic Medicines

PPT-PGN-08 - Appendix 1 (324kB)

Monitoring requirements for adult patients prescribed antipsychotics (except clozapine)

PPT-PGN-08 - Appendix 2 (332kB)

Monitoring requirements for children and young people (<18 years) prescribed antipsychotics (except clozapine)

PPT-PGN-08 - Appendix 3 (473kB)

Guidelines for the Management of QTc Prolongation in Adults Prescribed Antipsychotics

PPT-PGN-08 - Appendix 4 (257kB)

Medicines Related Physical Health Monitoring Drugs used to Manage ADHD (Children and Adults)

PPT-PGN-09 (504kB)

Use methotrexate and other cytotoxic Cytostatic agents

PPT-PGN-10 (539kB)

Guidelines for the Use of High Dose of Antipsychotic Therapy

PPT-PGN-10 - Appendix 1


PPT-PGN-10 - Appendix 2 (449kB)

Monitoring Requirements for HDAT

PPT-PGN-12 (485kB)

Buccal Administration of Midazolam by CNTW Staff as an Emergency Procedure for Patients with a Diagnosis of Epilepsy in Adults and Children

PPT-PGN-13 (485kB)

Midazolam for Sedation in Outpatient Clinics

PPT-PGN-13 - Appendix 1 (36kB)

Midazolam Sedation Risk Assessment

PPT-PGN-15 (228kB)

Subcutaneous Fluids

PPT-PGN-15 - Appendix 1 (136kB)

Subcutaneous Calculation Rates

PPT-PGN-15 - Appendix 2 (42kB)

Key Competencies for clinical procedure; Sub-cutaneous fluid administration

PPT-PGN-15 - Appendix 3 (54kB)

Fluid Balance Chart

PPT-PGN-17 (497kB)

Melatonin in Paediatric Sleep Disorders

PPT-PGN-18 (275kB)

Reducing Dosing Errors with Opioid Medicines

PPT-PGN-18 Appendix 1 (288kB)

Clinical Opiate Withdrawal Scale (COWS)

PPT-PGN-19 (768kB)

Safer Lithium Therapy

PPT-PGN-19 - Appendix 1 (231kB)

Lithium Level Guide for Prescribers)

PPT-PGN-19 - Appendix 2

Lithium Side Effects Scale -(LiSERS)-Restricted , Available on Local Intranet

PPT-PGN-19 - Appendix 3 (354kB)

Drug Interactions

PPT-PGN-19 - Appendix 4 (544kB)

Monitoring Requirements for patients on Lithium

PPT-PGN-19 - Appendix 5 (621kB)

Lithium Transfer Checklist

PPT-PGN-20 (429kB)

Prescribing Botulinum Toxin within CNTW Neuro-rehabilitation Services

PPT-PGN-21 (631kB)

Benzodiazepine and Z-drug prescribing in anxiety and insomnia

Appendix 3 (640kB)

Benzo and Zdrug flowchart

PPT-PGN-22 (1Mb)

Management of Acute Alcohol Withdrawal in Adults (Over 18)

PPT-PGN-23 (4Mb)

Oxygen use in Adults

PPT-PGN-24 (1Mb)

Management of Hyperprolactinaemia

PPT-PGN-25 (695kB)

Safe Prescribing of Valproate

PPT-PGN-26 (739kB)

Guidance for the in-patient use of opiate substitution therapy

PPT-PGN-27 (644kB)

Guidelines for the use of zuclopenthixol acetate IM injection

PPT-PGN-28 (247kB)

Prescribing Medicines and the Personality Disorder Pathway

PPT-PGN-28 - Appendix 1 (488kB)

Personality Disorder Good Practice Guidance

PPT-PGN-30 (872kB)

Safe Prescribing of Vitamin D